How Brain Regions Involved in Wakeful Rest May Play a Role in the Risk for Alzheimer’s Disease
Daydreaming puts the brain in a state of wakeful rest, allowing the connection of brain regions known as the Default Mode Network (DMN) to interact. The DMN is now a topic of investigation for researchers trying to understand why women are at a higher risk for Alzheimer's Disease than men.
Award-winning Associate Professor Yize Zhao Applies Innovative Statistical Methods to Advance Medical Science
In the Yale School of Public Health’s Department of Biostatistics, Associate Professor Yize Zhao is developing innovative statistical and machine learning methods to advance our knowledge of how the intricate processes within our brains impact our mental and physical well-being, and how these processes contribute to debilitating diseases like Alzheimer’s and depression.
Prior Experience Not Always A Plus For Dementia Caregiving
Millions of family caregivers provide essential emotional, physical, and social care to people living with dementia. As the global population ages, people providing care for more than one family member or close other across adulthood is becoming increasingly common. Yet little is known about the ways prior caregiving experiences shape an individual’s future preparedness when it comes to caring for additional people living with dementia.Source: Science Blog
Assistant Professor Tassos C. Kyriakides discusses the cognitive benefits of olive oil
A recent study co-authored by Yale School of Public Health Assistant Professor of Biostatistics Tassos C. Kyriakides finds that the daily consumption of extra-virgin olive oil could improve cognitive function in individuals with mild cognitive impairment
Breakthrough Alzheimer's drug slows symptoms, possible approval on horizon
Christopher Van Dyck, MD, professor of psychiatry, neurology, and neuroscience; director, Alzheimer's Disease Research Unit; and director, division of aging and geriatric psychiatry, speaks about Lecanemab, a breakthrough medication that appears to slow the progression of Alzheimer's disease symptoms by almost 30%.Source: FOX61
Associate Professor Xi Chen discusses global health challenges of Alzheimer’s disease
In recognition of November as Alzheimer’s Disease Awareness Month, Yale School of Public Health Associate Professor Xi Chen, an affiliate of Yale’s Alzheimer’s Disease Research Center, recently discussed the latest trends in Alzheimer’s disease research and treatment.
Health Headlines: New experimental Alzheimer’s drug; COVID’s effect on the body
New research has confirmed that COVID shots do affect periods, but experts are still studying how long it will take someone to recover from long COVID. Studies also showing that an experimental Alzheimer’s drug is slowing cognitive decline. Dr. Arjun Venkatesh, chief of the Emergency Medicine Administration at Yale and associate professor at the Yale School of Medicine, joined News 8 to discuss these exciting new discoveries in medicine, as well as the questions still left unanswered.Source: News 8 WTNH
Improving emergency care for older adults
In the United States, adults aged 50 and older make more than 40 million trips to emergency departments (EDs) each year. And that number is expected to grow, Ula Hwang, MD, MPH, professor of emergency medicine at Yale School of Medicine discusses importance of making geriatric emergency care a priority.Source: YaleNews
Hwang among team of GEAR Network researchers focused on improving emergency care for people living with dementia
Ula Hwang, MD co-authors a new collection of research papers that set out priority areas to better provide emergency care for people living with dementia in the United States. Four papers and an accompanying editorial were published today in the Journal of the American Medical Directors Association. The GEAR Network is focused on areas of research that need to be undertaken to provide the best care for people living with dementia when they arrive at the emergency department.
Introducing New Additions to the Outreach and Engagement Core of the Alzheimer's Disease Research Center
Carmen I. Carrión, Psy.D. has joined the ORE as an Associate Core Leader, joining Isis Burgos-Chapman, MD. Dr. Carrión is an Assistant Professor and a bilingual (Spanish) neuropsychologist in the department of Neurology.
What to Do About Aducanumab? Academic Memory Programs Brace for the Tough Questions
Academic medical centers are establishing committees and workgroups to develop standards and criteria for determining eligibility for the newly-approved and controversial Alzheimer's drug, aducanumab.Source: NeurologyToday